Medical Treatments for Chronic or Aggressive Diseases, Palliative Therapy and Nursery

Lu, Da Yong; Chen, Yu Zheng; Shen, Ying H.; Xu, Bin; Lu, Da Feng

doi:10.31031/nrs.2020.3.000556

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The different patho-physiological conditions and underlying diseases, like body mass index (BMI), [19][20] co-morbidity, [21][22] patient's ages and others will be considered and treated by personalized medicine [16][17][18] and palliative treatments. [30][31] Nurses will be able to report more detailed information to doctors and patient's care.…”

Section: New Therapeutic Strategies In Hospitalsmentioning

confidence: 99%

Nursery education, narrow-range or wide-range

Lu¹,

Chen²,

Lu³

2020

NCOAJ

View full text Add to dashboard Cite

A great proportion of healthcare efforts need high-quality medication and nursery. For high-quality nursery, education plays key roles. Currently, nurse education is divided into two major domains—specific technical mastering and wide-range of medical knowledge. It is suitable to different patterns of educational systems, such as nurse recruitments, personal goals and career design. This editorial addresses this part of medical challenges of nursery education—including education from medical schools and special education and performances in hospitals and healthcare centers.

show abstract

Section: New Therapeutic Strategies In Hospitalsmentioning

confidence: 99%

Nursery education, narrow-range or wide-range

Lu¹,

Chen²,

Lu³

2020

NCOAJ

View full text Add to dashboard Cite

show abstract

“…The different patho-physiological conditions and underlying diseases, like body mass index (BMI), 19,20 co-morbidities, 21,22 patient's ages and others will be considered and treated by personalized medicine [16][17][18] and palliative treatments. 30,31 Nurses should also notice detailed information to doctors and patient's care in this respect.…”

Section: Underlying Diseases and Co-morbiditymentioning

confidence: 99%

Nursery activity and quality, chemistry between doctors and nurses

Lu¹,

Chen²,

Lu³

2020

NCOAJ

View full text Add to dashboard Cite

show abstract

Anticancer Drug Development: Evaluative Architecture

2024

LDDD

View full text Add to dashboard Cite

Anticancer drug development is growing complexity and multi-factorials, which demands robust drug evaluative architecture in experimental and preclinical studies. To increase the number of drug licensing, biochemical, pharmacological, technical and economic changes (balance and integration) in evaluative systems should be focused in world labs. Despite a great progress, treatment breakthroughs and drug industry need new minds and more competitive technology (new generation of in vitro test systems) were emerging in the past. Overall, drug evaluative systems consisted half of anticancer drug development and licensing (medicinal chemistry and pharmacology in total) from initial screening to clinical validity. Its advances greatly impact the outcomes of drug production (rates of final drug licensing and efficacy of therapeutics in the clinic). In this regards, creative ideas and new techniques will change the norm and convention of drug screening and mechanic exploration in the future. This article provides multi-disciplinary approaches for experimental and preclinical anticancer drug evaluations, selections and combinations (chemistry and biomedicine). Future trends for drug evaluative systems are especially highlighted in depth, multilateral and multidisciplinary.

show abstract

Medical Treatments for Chronic or Aggressive Diseases, Palliative Therapy and Nursery

Cited by 3 publications

References 0 publications

Nursery education, narrow-range or wide-range

Nursery education, narrow-range or wide-range

Nursery activity and quality, chemistry between doctors and nurses

Anticancer Drug Development: Evaluative Architecture

Contact Info

Product

Resources

About